Chapters focus on the cellular and molecular mechanisms of various small-molecule compounds and inhibitors that target proteins that regulate the proteasome, ubiquitin ligases, ubiquitination pathway, and aggresome pathway in cancer
This book contains chapters written by experts in the field of the ubiquitin proteasome system and cancer. The authors have summarized current information on ubiquitin ligases and proteasomes as potential targets for cancer therapy. Topics covered in the book include an overview of ubiquitin ligases, deubiquitinating enzymes, and the proteasome. Specific diseases resulting from deregulated ubiquitin ligases, such as Von-Hippel-Lindau disease and Fanconi anemia are also discussed. Finally, novel approaches and drugs to target proteins involved in sumoylation, ubiquitination, and degradation are described.
Ubiquitin Ligases and Cancer.- The 26S Proteasome as a Therapeutic Target in Cancer: Beyond Protease Inhibitors?.- Targeting HAUSP: Killing Two Birds with One Stone.- Modulation of Protein Stability: Targeting the VHL Pathway.- Interrelationship of the Fanconi Anemia/BRCA Pathway.- Targeting the Sumoylation Pathway.- Proteasome Inhibitors.- Targeting Deubiquitinating Enzymes.- Proteolysis Targeting Chimeric Molecules.